212 related articles for article (PubMed ID: 33048465)
1. Treatment strategy of adding transcatheter arterial chemoembolization to sorafenib for advanced stage hepatocellular carcinoma.
Lee WC; Hung HC; Lee JC; Wang YC; Cheng CH; Wu TH; Lee CF; Wu TJ; Chou HS; Chan KM
Cancer Rep (Hoboken); 2021 Feb; 4(1):e1294. PubMed ID: 33048465
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
Zhang Y; Fan W; Wang Y; Lu L; Fu S; Yang J; Huang Y; Yao W; Li J
Oncologist; 2015 Dec; 20(12):1417-24. PubMed ID: 26446238
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
5. Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib.
Zheng J; Shao G; Luo J
Clin Transl Oncol; 2014 Nov; 16(11):1012-7. PubMed ID: 24894839
[TBL] [Abstract][Full Text] [Related]
6. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
[TBL] [Abstract][Full Text] [Related]
7. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
8. Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial.
Lee TY; Lin CC; Chen CY; Wang TE; Lo GH; Chang CS; Chao Y
Medicine (Baltimore); 2017 Sep; 96(37):e7655. PubMed ID: 28906355
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
[No Abstract] [Full Text] [Related]
10. The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma.
Kaibori M; Matsushima H; Ishizaki M; Kosaka H; Matsui K; Kariya S; Yoshii K; Sekimoto M
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1217-1224. PubMed ID: 33906315
[TBL] [Abstract][Full Text] [Related]
11. Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.
Fu S; Chen S; Liang C; Liu Z; Zhu Y; Li Y; Lu L
Oncotarget; 2017 Jun; 8(23):37855-37865. PubMed ID: 27911268
[TBL] [Abstract][Full Text] [Related]
12. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
Meng XC; Chen BH; Huang JJ; Huang WS; Cai MY; Zhou JW; Guo YJ; Zhu KS
World J Gastroenterol; 2018 Jan; 24(4):484-493. PubMed ID: 29398869
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW
AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059
[TBL] [Abstract][Full Text] [Related]
14. Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization.
Gu J; Zhang X; Cui R; Zhang J; Wang Z; Jia Y; Miao R; Dong Y; Ma X; Fan H; Wang H; Ren L; Li Y; Niu W; Zhang J; Qu K; Liu C
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):836-844. PubMed ID: 30614882
[TBL] [Abstract][Full Text] [Related]
15. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
[TBL] [Abstract][Full Text] [Related]
17. Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival.
Shimose S; Iwamoto H; Tanaka M; Niizeki T; Shirono T; Kajiwara A; Noda Y; Kamachi N; Okamura S; Nakano M; Kuromatsu R; Kawaguchi T; Koga H; Torimura T
Oncology; 2021; 99(12):756-765. PubMed ID: 34518483
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
19. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
